Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.
Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.
Multiple myeloma (MM) remains an incurable blood cancer, but recent advancements in treatment have significantly improved patient prognosis and quality of life. UK-based specialist diagnostic company The Binding Site has developed a new strategy that monitors pre-cancerous conditions associated with MM as well as treatment success, helping to guide therapeutic pathways with more accurate information.
Ralf Griebel, Head of the Partnering Business Division